The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to Arrowhead Research's patent application NO.13/336,028 covering dynamic polyconjugate (DPC) siRNA delivery system.
The patent entitled, 'In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages,' expands the DPC platform, broadly protecting the company's next generation DPC polymer masking technology.
The company said DPCs can be engineered for long circulation times and improved tissue-targeting characteristics by using the masking technology.
In addition, hepatocyte-targeted DPCs formulated using the new masking technology have shown to be highly potent upon subcutaneous administration.
Arrowhead Research president and CEO Chris Anzalone said the patent protects a new masking chemistry that broadens the reach of DPC-enabled RNAi therapeutics.
"It enables efficient subcutaneous delivery of siRNA and opens up new therapeutic area targets including oncology," Anzalone added.
"Arrowhead scientists continue to discover innovative solutions for siRNA delivery and we look forward to providing updates on how these technologies are being deployed to create new drug candidates."
